FDA Generic Rx Reforms Contribute To Medicare Budget Squeeze
Executive Summary
CBO is predicting only minor savings to the Medicare prescription drug program through Waxman/Hatch reforms contained in the Senate and House versions of the Medicare bill in light of previous reforms announced by FDA
You may also be interested in...
Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution
Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution
CMS Expected To Delay AWP Regulation; Medicare Conferees Want Credit
The Centers for Medicare & Medicaid Services is expected to hold off on issuing a final regulation reforming the AWP reimbursement methodology to allow Medicare conferees the chance to complete work on the issue